Antitumor immune cycle proteins and HPV status in patients with HSIL and cervical cancer

Background. Cervical cancer (CC) is a common malignant tumor among women worldwide. The anti-tumor immune cycle (AIC) is a necessary molecular mechanism that prevents the occurrence and progression of a tumor. It is known that during the development of CC, several mechanisms disrupt the AIC and cont...

Full description

Bibliographic Details
Main Authors: Elena V. Kayukova, Tatiana E. Belokrinitskaya, Svetlana V. Romanyuk
Format: Article
Language:Russian
Published: IP Berlin A.V. 2023-01-01
Series:Гинекология
Subjects:
Online Access:https://gynecology.orscience.ru/2079-5831/article/viewFile/112565/pdf
_version_ 1797945146021511168
author Elena V. Kayukova
Tatiana E. Belokrinitskaya
Svetlana V. Romanyuk
author_facet Elena V. Kayukova
Tatiana E. Belokrinitskaya
Svetlana V. Romanyuk
author_sort Elena V. Kayukova
collection DOAJ
description Background. Cervical cancer (CC) is a common malignant tumor among women worldwide. The anti-tumor immune cycle (AIC) is a necessary molecular mechanism that prevents the occurrence and progression of a tumor. It is known that during the development of CC, several mechanisms disrupt the AIC and contribute to tumor progression. Recent data show the role of human papillomavirus (HPV) in the AIC regulation as a mechanism for the emergence of tumor resistance to the anti-tumor immune response. Aim. To study the levels of AIC proteins (sCD25, 4-1BB, B7.2, TGF-b1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9, sCD27, PD-L2) in patients with high-grade squamous intraepithelial lesion (HSIL) and CC, depending on the HPV status. Materials and methods. A prospective study enrolled women of reproductive age with HSIL (n=53) and stage IIII СС (n=93). The control group included female volunteers without cervical abnormalities (n=30). The study material was the cervical epithelium. Study methods: flow cytometry, diagnostics using the polymerase chain reaction for HPV status and viral load. Statistical processing was performed using the IBM SPSS Statistics version 25.0 software package using non-parametric statistics methods. Results. The obtained data indicate an expression increase of AIC inhibitors: PD-1 and PD-L2 in patients with HPV infection and sCD27 in patients with mono-HPV infection. There were no significant differences in the levels of AIC proteins, depending on the HPV viral load in patients with HSIL and CC. Conclusion. The effect of HPV infection and its type on regulating the expression of specific AIC proteins has been established, which is one of the mechanisms of tumor progression.
first_indexed 2024-04-10T20:50:39Z
format Article
id doaj.art-d6372620290547c3a24cabe6547c9b41
institution Directory Open Access Journal
issn 2079-5696
2079-5831
language Russian
last_indexed 2024-04-10T20:50:39Z
publishDate 2023-01-01
publisher IP Berlin A.V.
record_format Article
series Гинекология
spelling doaj.art-d6372620290547c3a24cabe6547c9b412023-01-23T16:49:07ZrusIP Berlin A.V.Гинекология2079-56962079-58312023-01-0124652552810.26442/20795696.2022.6.20197779472Antitumor immune cycle proteins and HPV status in patients with HSIL and cervical cancerElena V. Kayukova0https://orcid.org/0000-0002-4682-1811Tatiana E. Belokrinitskaya1https://orcid.org/0000-0002-5447-4223Svetlana V. Romanyuk2Chita State Medical AcademyChita State Medical AcademyChita State Medical AcademyBackground. Cervical cancer (CC) is a common malignant tumor among women worldwide. The anti-tumor immune cycle (AIC) is a necessary molecular mechanism that prevents the occurrence and progression of a tumor. It is known that during the development of CC, several mechanisms disrupt the AIC and contribute to tumor progression. Recent data show the role of human papillomavirus (HPV) in the AIC regulation as a mechanism for the emergence of tumor resistance to the anti-tumor immune response. Aim. To study the levels of AIC proteins (sCD25, 4-1BB, B7.2, TGF-b1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9, sCD27, PD-L2) in patients with high-grade squamous intraepithelial lesion (HSIL) and CC, depending on the HPV status. Materials and methods. A prospective study enrolled women of reproductive age with HSIL (n=53) and stage IIII СС (n=93). The control group included female volunteers without cervical abnormalities (n=30). The study material was the cervical epithelium. Study methods: flow cytometry, diagnostics using the polymerase chain reaction for HPV status and viral load. Statistical processing was performed using the IBM SPSS Statistics version 25.0 software package using non-parametric statistics methods. Results. The obtained data indicate an expression increase of AIC inhibitors: PD-1 and PD-L2 in patients with HPV infection and sCD27 in patients with mono-HPV infection. There were no significant differences in the levels of AIC proteins, depending on the HPV viral load in patients with HSIL and CC. Conclusion. The effect of HPV infection and its type on regulating the expression of specific AIC proteins has been established, which is one of the mechanisms of tumor progression.https://gynecology.orscience.ru/2079-5831/article/viewFile/112565/pdfhsilcervical canceranti-tumor immune cyclehuman papilloma virus
spellingShingle Elena V. Kayukova
Tatiana E. Belokrinitskaya
Svetlana V. Romanyuk
Antitumor immune cycle proteins and HPV status in patients with HSIL and cervical cancer
Гинекология
hsil
cervical cancer
anti-tumor immune cycle
human papilloma virus
title Antitumor immune cycle proteins and HPV status in patients with HSIL and cervical cancer
title_full Antitumor immune cycle proteins and HPV status in patients with HSIL and cervical cancer
title_fullStr Antitumor immune cycle proteins and HPV status in patients with HSIL and cervical cancer
title_full_unstemmed Antitumor immune cycle proteins and HPV status in patients with HSIL and cervical cancer
title_short Antitumor immune cycle proteins and HPV status in patients with HSIL and cervical cancer
title_sort antitumor immune cycle proteins and hpv status in patients with hsil and cervical cancer
topic hsil
cervical cancer
anti-tumor immune cycle
human papilloma virus
url https://gynecology.orscience.ru/2079-5831/article/viewFile/112565/pdf
work_keys_str_mv AT elenavkayukova antitumorimmunecycleproteinsandhpvstatusinpatientswithhsilandcervicalcancer
AT tatianaebelokrinitskaya antitumorimmunecycleproteinsandhpvstatusinpatientswithhsilandcervicalcancer
AT svetlanavromanyuk antitumorimmunecycleproteinsandhpvstatusinpatientswithhsilandcervicalcancer